BNT111-01

Research code: BNT111-01
Research name: Randomised, open-label, phase II research with BNT111 and cemiplimab in combination or monotherapy in patients with refractory anti-PD-1 antibody treatment/relapsed, inoperable stage III or IV melanoma.
Indication: melanoma
Principal researcher: Ewa Chmielowska, MD, PhD
Research population: patients with stage III or IV melanoma who have experienced treatment failure after immunotherapy
Investigated drug: BNT111 mRNA vaccine in combination with cemiplimab acting on PD-L1 and PD-L2 receptors (combination of 2 different mechanisms affecting the immune system, increasing the immune response)